Skip Navigation
Visitor Guideline Update: Due to respiratory virus season, children 12 and under are not permitted to visit patients in multiple settings. Additionally, everyone is required to mask in patient rooms and other designated areas. Learn more.

Finding a Better Way to Treat and Manage Multiple Sclerosis

Neurosciences Institute’s multiple sclerosis center is recognized as a leader in research and treatment by the National Multiple Sclerosis Society. Our nationally known, fellowship-trained specialists work with industry sponsors and others to find better ways to treat and manage the symptoms of multiple sclerosis (MS).

With access to a large and diverse population of MS patients and review by a fast IRB process, studies can be enrolled and approved quickly at our center. This makes us an attractive location for industry-sponsored trials looking to quickly enrolling patients for much-needed treatments and innovative approaches.

We are currently enrolling the following studies:

  • FLUENT - A 12-month, prospective, multicenter, two-cohort, non-randomized, open-label study in adult patients with relapsing multiple sclerosis to investigate changes in immune phenotype biomarkers after treatment with 0.5 mg fingolimod (FTY720)
  • LEM-COG - A 24-month, prospective, observational study to evaluate neurocognitive function and safety in patients with relapsing multiple sclerosis who are initiating LEMTRADA® treatment in routine clinical practice